JPMorgan acted as sole book running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target raised to $58 from $51 at Cantor Fitzgerald
- Harmony Biosciences price target raised to $59 from $56 at Oppenheimer
- Harmony Biosciences: Strong Q3 and Future Growth
- Harmony Biosciences announces 8M share offering of common stock for holders
- Harmony Biosciences reports Q3 adjusted EPS $1.03, consensus 66c